Journal article icon

Journal article

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.

Abstract:

Background

Mepolizumab significantly reduces exacerbations in patients with severe eosinophilic asthma. The early identification of patients likely to receive long-term benefit from treatment could ensure effective resource allocation.

Objective

To assess potential continuation rules for mepolizumab in addition to initiation criteria defined as 2 or more exacerbations in the previous year and blood eosinophil counts of 150 cells/mL or more at initiation or 300 cel...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.jaip.2017.11.026

Authors


More by this author
Role:
Author
ORCID:
0000-0003-0016-9773
Expand authors...
GlaxoSmithKline More from this funder
Publisher:
Elsevier Publisher's website
Journal:
Journal of Allergy and Clinical Immunology: In Practice Journal website
Volume:
6
Issue:
3
Pages:
874-882.e4
Publication date:
2017-12-01
Acceptance date:
2017-11-15
DOI:
EISSN:
2213-2201
ISSN:
2213-2198
Pmid:
29258789
Source identifiers:
813157
Language:
English
Keywords:
Pubs id:
pubs:813157
UUID:
uuid:388560b5-4a45-4839-a9af-d13d8dcfb55f
Local pid:
pubs:813157
Deposit date:
2018-03-02

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP